SCHEMBL4707752

SCHEMBL4707752

COc1ccc(N)cc1O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
KDM4E B2RXH2 3/20 0.43
GAA P10253 3/20 0.43
ALDH1A1 P00352 5/20 0.40
EP300 Q09472 1/20 0.39
KAT8 Q9H7Z6 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
NR4A1 P22736 1/20 0.39
USP2 O75604 1/20 0.37
IDO1 P14902 1/20 0.37
CYP19A1 P11511 2/20 0.36
LMNA P02545 1/20 0.36
BRD4 O60885 1/20 0.35
IMPDH2 P12268 1/20 0.35
IMPDH1 P20839 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4709625 0.94 MAPT (0.46) MAPTKDM4EGAAALDH1A1EP300
SCHEMBL29062461 0.79 ENPP2 (0.36) IDO1CA12CA1CA2CA4
SCHEMBL4423511 0.79 ALDH1A1 (0.55) MAPTKDM4EALDH1A1TSHRHTT
SCHEMBL6139350 0.79 SMN1; SMN2 (0.40) MAPTKDM4EGAAALDH1A1HTT
SCHEMBL30583955 0.79 ENPP2 (0.36) IDO1CA12CA1CA2CA4
SCHEMBL4709649 0.78 HTT (0.49) MAPTGAAALDH1A1MAPK1HTT
SCHEMBL5062220 0.78 KDM4E (0.43) MAPTKDM4EGAAALDH1A1TSHR
SCHEMBL6257880 0.77 NQO2 (0.34) MAPTKDM4EGAAALDH1A1EP300
SCHEMBL30108108 0.77 NR3C2 (0.40) KDM4E
SCHEMBL5334814 0.77 NPC1 (0.43) MAPTKDM4EGAAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556055-B1 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY VIA PHARMACEUTICALS INC (US) 2008-10-29 EP disclosed
US-20060128695-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses NEURO3D (FR) 2006-06-15 US disclosed
EP-1556055-A2 USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY NEURO3D (FR) 2005-07-27 EP disclosed
WO-2004041258-A2 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES NEURO3D (FR) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128695-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses PDE7A, PDE4A, PDE4B MAPT 3649/4885KDM4E 2333/4885GAA 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.